BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Sudarshan Chemical Industries Ltd.’s numbers came in below our estimates due to lower-than-expected growth in pigments segment.
Reported revenue de-growth of 12.3% YoY to Rs 528 crore, led by lower offtake from pigments (down 13.7%) even as other segment grew 7%.
Gross margins increased 24 basis points YoY to ~40.8% while Ebitda margins contracted 439 bps YoY to 7.9% due to escalation in other expenses (up 5.8% YoY).
Sudarshan Chemical's Ebitda declined 43.6% YoY to Rs 41.6 crore. The decline was led by elevated level of energy cost and foreign exchange loss of Rs 8.6 crore. Profit after tax was down 98.4% YoY to Rs 60 lakh.
Click on the attachment to read the full report:
Also Read: Navin Fluorine Q3 Results Review - Strong Beat Across Segments; Valuations Fair: ICICI Direct
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU
![](https://images.assettype.com/bloombergquint/2022-07/bc111b70-3830-4f34-9b4f-d7bf00df3abb/Tablets_and_capsules_blisters_arranged_for_photograph___Photo_Roberto_Sorin_Unsplash_.jpg?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
Pharma Q4 Result Review - Strong Show In U.S., Lower Raw Material Cost Boost Performance: ICICI Securities
![timelogo](/images/amp-time.png)
![](https://images.assettype.com/bloombergquint/2022-05/254f920c-8e97-427d-9e78-134b73999637/A_healthcare_worker__Photo_Hush_Naidoo_Jade_Source_Unsplash_.jpg?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
Healthcare Q4 Result Review - Hospital Capex To Surge; Diagnostics Growth At An Inflection: ICICI Securities
![timelogo](/images/amp-time.png)
![](https://images.assettype.com/bloombergquint/2023-04/4993497f-6a19-49d5-9edc-eae14e30fcbf/Chemicals_solutions_in_test_tubes_sits_inside_a_R_D_lab___Source_pexels_.jpg?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
Galaxy Surfactants Q4 Results Review - As Expected, Ebitda/kg Guidance Raised: ICICI Securities
![timelogo](/images/amp-time.png)
![](https://images.assettype.com/bloombergquint/2023-09/d79fabc7-ead6-4d16-861f-5cdfafc74f6f/Sudarshan_Chemicals_India_Ltd___Source_Company_website_.png?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
Sudarshan Chemical Q4 Results Review - Strong Quarter, Significantly Improved Outlook: Dolat Capital
![timelogo](/images/amp-time.png)